hat
David Adams, yon jenetisyen kansè nan bienvenus Trust Sanger Enstiti a, di rechèch la ta kapab ede doktè travay konnen ki moun ki gen plis chans yo benefisye de terapi nouvo ki esplwate sistèm iminitè a. "Itilize nan pi gran nan konesans sa a se nan travay konnen ki pasyan ki gen plis chans yo dwe ki ka trete,"Li te di. "Pwoblèm nan ak immunotherapies sa yo se yo trè chè epi nou pa konnen ki moun ki pral reponn epi ki pa pral."
eng
David Adams, a cancer geneticist at the Wellcome Trust Sanger Institute, said the research could help doctors work out who is most likely to benefit from new therapies that exploit the immune system. “The greatest use of this knowledge is in working out which patients are most likely to be treatable,” he said. “The issue with these immunotherapies is they are extremely expensive and we don’t know who will respond and who won’t.”